Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Thomas Jefferson University
Radiation Therapy Oncology Group
Roswell Park Cancer Institute
Fox Chase Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)